<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02757144</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWP14012001</org_study_id>
    <nct_id>NCT02757144</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Male Volunteers</brief_title>
  <official_title>A Dose Block-randomized, Double-blind, Placebo- and Active-controlled, Single and Multiple Dosing, Dose-escalation Clinical Phase 1 Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose block-randomized, double-blind, placebo- and active-controlled, single and
      multiple dosing, dose-escalation clinical phase 1 trial to investigate the safety,
      tolerability, pharmacokinetics and pharmacodynamics of DWP14012 after oral administration in
      healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and percentage of Participants With Adverse Events (AE)</measure>
    <time_frame>Day -2(Randomization) to Day 11~18(Post-study visit)</time_frame>
    <description>All AE standardized using MedDRA was assessed by investigator using the protocol defined grading system. Intensity was categorized as mild, moderate adn severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and percentage of Participants With Adverse Drug Reactions (ADR)</measure>
    <time_frame>Day -2(Randomization) to Day 11~18(Post-study visit)</time_frame>
    <description>An adverse drug reaction (ADR) is an injury caused by taking an investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Vital Sign findings</measure>
    <time_frame>Day -2(Randomization) to Day 11~18(Post-study visit)</time_frame>
    <description>Blood pressure, pulse and body temperature were tested. The Average, Median, Standard Deviation, Min, Max values will be calculated to assess the safety/tolerability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Electrocardiogram(12-lead ECG) findings</measure>
    <time_frame>Day -2(Randomization) to Day 11~18(Post-study visit)</time_frame>
    <description>Ventricular rate, RR interval, PR interval, QRS duration, QTcB and QTcF were recorded. The results of 12-lead ECG will be categorized Normal/Abnormal NCS(No clinically significant)/Abnormal CS(clinically significant).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Laboratory results</measure>
    <time_frame>Day -2(Randomization) to Day 11~18(Post-study visit)</time_frame>
    <description>Hematology, Blood chemistry, Coagulation and Urinalysis were tested. The Average, Median, Standard Deviation, Min, Max values will be calculated to assess the safety/tolerability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum concentration of DWP14012</measure>
    <time_frame>0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours</time_frame>
    <description>in single ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss: Maximum concentration of DWP14012 at steady state</measure>
    <time_frame>0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24h, Day 3-6 pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours</time_frame>
    <description>in multiple ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss: Minimum concentration of DWP14012 at steady state</measure>
    <time_frame>0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24h, Day 3-6 pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours</time_frame>
    <description>in multiple ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time of maximum concentration</measure>
    <time_frame>0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours</time_frame>
    <description>in single ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss: Time of maximum concentration at steady state</measure>
    <time_frame>0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24h, Day 3-6 pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours</time_frame>
    <description>in multiple ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast: Area under the plasma concentration-time curve from time 0 to 48hours</measure>
    <time_frame>0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours</time_frame>
    <description>in single ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf: Area under the plasma concentration-time curve from time 0 to infinity</measure>
    <time_frame>0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours</time_frame>
    <description>in single ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau: Area under the plasma concentration-time curve from time 0 to tau(dosing interval)</measure>
    <time_frame>0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24h, Day 3-6 pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours</time_frame>
    <description>in multiple ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2: Elimination half-life</measure>
    <time_frame>0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours</time_frame>
    <description>in single ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2: Elimination half-life</measure>
    <time_frame>0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24h, Day 3-6 pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours</time_frame>
    <description>in multiple ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of total time that the intragastric pH was above 4</measure>
    <time_frame>Day 1</time_frame>
    <description>After single administration of the investigational products, 24hr gastric pH monitoring started.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of total time that the intragastric pH was above 4</measure>
    <time_frame>Day 7</time_frame>
    <description>After multiple administration of the investigational products, 24hr gastric pH monitoring started.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum gastrin concentration profile</measure>
    <time_frame>Day -2(Randomization) to Day 11~18(Post-study visit)</time_frame>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1: DWP14012 Amg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 Amg, tablets, orally, single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: DWP14012 Bmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 Bmg, tablets, orally, single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: DWP14012 Cmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 Cmg, tablets, orally, single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: DWP14012 Dmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 Dmg, tablets, orally, single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: DWP14012 Emg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 Emg, tablets, orally, single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: DWP14012 Fmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 Emg, tablets, orally, single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1-6: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>DWP14012 placebo-matching tablets, Active-control placebo-matching tablets, orally, single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1-6: Esomeprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nexium® tablets, orally, single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7: DWP14012 Amg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 Amg, tablets, orally, repeated dose administration(for 7days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8: DWP14012 Bmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 Bmg, tablets, orally, repeated dose administration(for 7days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9: DWP14012 Cmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 Cmg, tablets, orally, repeated dose administration(for 7days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7-10: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>DWP14012 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 7days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7-10: Esomeprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nexium®, orally, repeated dose administration(for 7days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9: DWP14012 Dmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 Dmg, tablets, orally, repeated dose administration(for 7days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012</intervention_name>
    <description>DWP14012 tablets</description>
    <arm_group_label>Cohort 1: DWP14012 Amg</arm_group_label>
    <arm_group_label>Cohort 2: DWP14012 Bmg</arm_group_label>
    <arm_group_label>Cohort 3: DWP14012 Cmg</arm_group_label>
    <arm_group_label>Cohort 4: DWP14012 Dmg</arm_group_label>
    <arm_group_label>Cohort 5: DWP14012 Emg</arm_group_label>
    <arm_group_label>Cohort 6: DWP14012 Fmg</arm_group_label>
    <arm_group_label>Cohort 7: DWP14012 Amg</arm_group_label>
    <arm_group_label>Cohort 8: DWP14012 Bmg</arm_group_label>
    <arm_group_label>Cohort 9: DWP14012 Cmg</arm_group_label>
    <arm_group_label>Cohort 9: DWP14012 Dmg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>DWP14012 placebo-matching tablets, Active control placebo-matching tablets</description>
    <arm_group_label>Cohort 1: DWP14012 Amg</arm_group_label>
    <arm_group_label>Cohort 2: DWP14012 Bmg</arm_group_label>
    <arm_group_label>Cohort 3: DWP14012 Cmg</arm_group_label>
    <arm_group_label>Cohort 4: DWP14012 Dmg</arm_group_label>
    <arm_group_label>Cohort 5: DWP14012 Emg</arm_group_label>
    <arm_group_label>Cohort 6: DWP14012 Fmg</arm_group_label>
    <arm_group_label>Cohort 1-6: Placebo</arm_group_label>
    <arm_group_label>Cohort 1-6: Esomeprazole</arm_group_label>
    <arm_group_label>Cohort 7: DWP14012 Amg</arm_group_label>
    <arm_group_label>Cohort 8: DWP14012 Bmg</arm_group_label>
    <arm_group_label>Cohort 9: DWP14012 Cmg</arm_group_label>
    <arm_group_label>Cohort 7-10: Placebo</arm_group_label>
    <arm_group_label>Cohort 7-10: Esomeprazole</arm_group_label>
    <arm_group_label>Cohort 9: DWP14012 Dmg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>Nexium®</description>
    <arm_group_label>Cohort 1-6: Esomeprazole</arm_group_label>
    <arm_group_label>Cohort 7-10: Esomeprazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males aged between 19 and 50 at screening

          -  Those whose weight is between 55 and 90 kg and BMI is between 18.0 and 27.0

          -  Those who are adequate to be subjects in this study upon judgment of the investigator
             after physical examination, clinical laboratory test, examination by interview, etc

        Exclusion Criteria:

          -  Those who have clinical significant liver, kidney, nervous system, respiratory,
             endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or
             past history

          -  Those who have gastrointestinal diseases or past history of gastrointestinal diseases
             (gastrointestinal ulcer, gastritis, gastrospasm, gastroesophageal reflux, Crohn's
             disease etc.) that may affect safety and pharmacokinetic/pharmacodynamic evaluation of
             study drug, and those who have past history of gastrointestinal surgery (however,
             except simple appendectomy and herniotomy)

          -  Those who have been Helicobacter pylori positive

          -  Those whose plasma AST (SGOT) and ALT (SGPT) exceed 1.5 times to the upper limit of
             the normal range in screening including additional examinations prior to randomization

          -  Those who have anatomical disability in insertion and maintenance of pH meter catheter
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2016</study_first_submitted>
  <study_first_submitted_qc>April 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2016</study_first_posted>
  <last_update_submitted>April 23, 2017</last_update_submitted>
  <last_update_submitted_qc>April 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

